ClinicalTrials.gg
CompletedNCT07194785RY-CHD ScreenUpdated Mar 3, 2026

AI-Assisted Smart Stethoscope Screening for Structural Heart Disease in School Students in Ruyang County

An observational study in Structural Heart Disease, sponsored by Heart Health Research Center. Completed at 1 site in China. Open to participants aged 10 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Heart Health Research Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,614
Ages
10 Years to 18 Years
Sex
All
01

Study summary

The goal of this observational diagnostic study is to evaluate whether an artificial intelligence (AI)-enabled smart stethoscope can accurately detect structural heart disease in school-aged children and adolescents (10-18 years) in Ruyang County, China.

The main questions it aims to answer are:

Can the smart stethoscope reliably identify students with cardiac murmurs that indicate possible structural heart disease? How well do the sensitivity, specificity, and predictive values of the smart stethoscope compare with standard echocardiography?

Researchers will compare AI-assisted stethoscope screening results with echocardiography (gold standard) to see if the device can be used as an effective early screening tool.

Participants will:

Undergo a heart sound screening using the AI-enabled smart stethoscope (3-5 minutes).

If screening is positive, receive a free echocardiogram at Ruyang County People's Hospital.

A small sample of students with negative screening results will also receive echocardiography to check for missed cases.

Read the detailed description

Structural heart disease (SHD), including congenital and acquired cardiac abnormalities, is a leading cause of morbidity in children and adolescents. Cardiac murmurs are common clinical signs, but traditional auscultation has limited accuracy in school or community settings due to examiner variability and limited access to echocardiography.

This study evaluates the performance of an artificial intelligence (AI)-enabled smart stethoscope for school-based screening of SHD in primary and secondary students in Ruyang County, China. The device integrates high-sensitivity acoustic sensors, noise-reduction technology, and deep learning algorithms to provide automated interpretations of heart sounds within seconds. Prior validation studies have demonstrated high sensitivity (>80%) and specificity (>90%) for congenital heart disease and up to 94% sensitivity and 98% specificity for rheumatic heart disease.

Screening will be conducted by trained personnel at four standard cardiac auscultation sites. Students with abnormal AI findings will undergo repeat testing and, if confirmed, will be referred for transthoracic echocardiography at Ruyang County People's Hospital. A subset of students with negative AI screens will also receive echocardiography to estimate false-negative rates.

Data will be analyzed using 2×2 contingency tables to compare AI screening results with echocardiography, and diagnostic performance metrics including sensitivity, specificity, positive predictive value, and negative predictive value will be calculated with 95% confidence intervals. Agreement between AI-assisted auscultation and echocardiography will be assessed using Cohen's kappa.

This study will provide evidence on the feasibility, accuracy, and scalability of AI-enabled smart stethoscopes for early SHD detection in school-based, low-resource settings.

02

Conditions studied

  • Structural Heart Disease
03

In context

Lead sponsor

Heart Health Research Center is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from primary and secondary schools in Ruyang County, Henan Province, China. Screening will be conducted on-site at schools by trained personnel using AI-enabled smart stethoscopes. Students identified as having abnormal findings will be referred to the Cardiology Department of Ruyang County People's Hospital for confirmatory transthoracic echocardiography. A subset of students with normal screening results will also undergo echocardiography to estimate false-negative rates.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. School students aged 10-18 years.
  2. Able to cooperate with cardiac auscultation.
  3. Student and parent/guardian provide written .

Exclusion criteria

Exclusion Criteria:

  1. Student or parent/guardian declines participation.
  2. Inability or unwillingness to follow screening procedures or cooperate with cardiac auscultation.
  3. Refusal to undergo standard transthoracic echocardiography or cardiology evaluation.
  4. Previously diagnosed structural heart disease.
  5. Chest wall deformities or skin conditions that may interfere with auscultation.
  6. Fever ≥37.5 °C on the day of examination, or severe developmental delay or other conditions preventing cooperation with the examination.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,614 participants (actual)
Target follow-up
7 Days
Patient registry
Yes

Groups and cohorts

  • Screen group

    Diagnostic Test: AI-Assisted Cardiac Auscultation using the HearTech Smart Stethoscope

Interventions

  • Diagnostic testAI-Assisted Cardiac Auscultation using the HearTech Smart Stethoscope

    This intervention utilizes the HearTech smart stethoscope, where trained research personnel perform standardized examinations of four cardiac auscultation areas on subjects. The integrated AI algorithm analyzes heart sounds in real time and automatically generates reports. An initial positive detection triggers a repeat testing process, with the algorithm ultimately determining a positive screening result based on three detection outcomes (any two positive). This AI-assisted auscultation system is designed to achieve large-scale, standardized, and highly efficient preliminary heart murmur screening.

06

What researchers measure

Primary outcomes

  1. Specificity of AI-enabled smart stethoscope

    Proportion of students with a "screening negative" report by the smart stethoscope who are confirmed to have no structural heart disease by transthoracic echocardiography.

    Time frame: From enrollment to the end of screen at 4 months.

  2. Positive Predictive Value (PPV) of AI-enabled smart stethoscope

    Proportion of students with two consecutive "screening positive" reports by the smart stethoscope who are confirmed to have structural heart disease by echocardiography.

    Time frame: From enrollment to the end of screen at 4 months.

  3. Negative Predictive Value (NPV) of AI-enabled smart stethoscope

    Proportion of a random subset of students with a "screening negative" report by the smart stethoscope who are confirmed to have no structural heart disease by echocardiography.

    Time frame: From enrollment to the end of screen at 4 months.

07

Study locations

1 site
  • Ruyang County People's Hospital
    Luoyang, Henan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Dec 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 26, 2025
StartActual
Oct 27, 2025
Primary completionActual
Dec 29, 2025
CompletionActual
Jan 5, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07194785
Lead sponsor
Heart Health Research Center
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Oct 27, 2025
Primary completion
Dec 29, 2025
Completion
Jan 5, 2026
Last update
Mar 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion